newsfilter
← Latest News
GlobeNewswire·

Cellectis to Report Third Quarter Financial Results on November 12, 2026

  • Cellectis will report financial results for the third quarter of 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.
  • An investor conference call & webcast regarding the Q3 2026 results & business updates will take place on Friday, November 13, 2026 at 8:00 a.m. ET / 2:00 p.m. CET.
  • Cellectis is a genome engineering company headquartered in Paris, France, with locations in New York & Raleigh, NC, developing genetic medicines for diseases requiring lifetime treatment.
  • The company is listed on the Nasdaq Global Market (ticker: CLLS) & Euronext Growth (ticker: ALCLS).
  • Dial-in numbers for the call are +1-833-354-6854 (Toll Free US & Canada) & +1-785-838-9343 (US/International Toll), with Conference ID CLLSQ3.
Company
Cellectis Inc.
Keywords
Paris Stock Exchange:ALCLS, Cellectis Inc., earnings call, in vivo, in vivo gene editing, Q3 2026